Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 May 1;106(11):1779–1789. doi: 10.1038/bjc.2012.176

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2012 Cancer Research UK

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Differential responses to combination therapy in a panel of primary ovarian xenografts. Five human xenografts grown from material obtained primary ovarian cancer patients were treated with the trastuzumab plus pertuzumab combination. HOX424 displayed a complete growth response, HOX516 and HOX486 show a minor response and HOX493 and OV1002 were unresponsive. Xenografts were collected on day 7. Mean values (±s.e.) of at least four tumours/group are shown. Dashed lines show changes for immunohistochemistry, solid lines for AQUA quantitative immunofluorescence.